Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.
At ATTD 2023, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, have an extended conversation with the new chief operating officer at Dexcom, Jake Leach, to discuss the global and US rollouts of the Dexcom G7 and what the future might hold for Dexcom.
Drs Diana Isaacs and Natalie Bellini highlight the need for engaging patients in shared decision-making and addressing social determinants of health in diabetes and obesity management in adults and pediatric patients.
Scott Kahan, MD, MPH, discusses with Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, how the controversial use of new diabetes and obesity medications is creating access issues for people who really need these medications, and shares strategies to initiate the conversation about weight management with patients.
Dr Scott Kahan shares the latest updates to the 2023 ADA Standards of Care related to weight management and describes the different weight loss approaches recommended by the ADA.
Scott Kahan, MD, MPH, discusses the shortcomings of the current staging systems used for overweight and obesity and recommends the use of weight-related health and functional status in addition to BMI.
Drs Diana Isaacs and Natalie Bellini highlight the need for improved screening, greater awareness of clinical trial opportunities, and clinician education to improve early diagnosis and outcomes for people with T1D.
Sumita Singh, a T1D advocate, discusses with Diana Isaacs and Natalie Bellini how teplizumab and other advances are providing hope to the T1D community and talks about the challenges and needs of a diverse T1D patient population.
Sumita Singh, a T1D advocate, discusses her family’s decision to enroll their daughter Bella in a clinical trial for T1D and shares their experience.
Sumita Singh shares about her daughter Bella’s type 1 diabetes (T1D) diagnosis and how their family navigated the logistical and emotional challenges of receiving a T1D diagnosis.
Drs Diana Isaacs and Natalie Bellini discuss the everyday challenges of managing type 1 diabetes and underscore the need for new treatments to improve the quality of life for people living with type 1 diabetes
Expert healthcare practitioners discuss the potential of CGM and other technology to identify signs of type 1 diabetes.
Dr Emily Sims reviews the study design of the clinical trials with teplizumab and shares key findings from the completed phase 2 trial.
Dr Emily Sims provides an overview of the stages of type 1 diabetes (T1D) and explains how teplizumab slows the immune-mediated destruction of beta cells.
In this episode of Diabetes Dialogue, ours hosts discuss the clearance of Tidepool Loop, what is unique about the app’s customizability and compatibility with other diabetes technologies, and other top points for people with diabetes and members of the diabetes care team to consider with the technology moving into the future.
In their final episode from the ADCES 2nd Annual Diabetes Technology Conference, our hosts are joined by Gary Scheiner, MS, and Jennifer Okemah, RD, to discuss their businesses, a glimpse into their personal journeys into becoming diabetes care and education specialists, and how they have seen their role in improving care transform in recent years.
In the January 2023 episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, offer their perspective on the American Academy of Pediatric’s obesity guidance, the results of Nature Medicine study examining AID in type 2 diabetes study, and new data calling into question the appropriate target for time in range for people with types 2 diabetes.
In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Steven Russell, MD, PhD, the chief medical officer of Beta Bionics, for a discussion around his journey to becoming CMO as well as a deep dive into the iLet Bionic Pancreas and its potential in diabetes management.
Drs Diana Isaacs and Natalie Bellini share takeaways for clinicians exploring non-invasive insulin delivery methods to manage diabetes.
Expert healthcare practitioners discuss ongoing studies of inhaled insulin in T2D and how it might fit into treatment protocol.
Dr Diana Isaacs provides an overview of the latest developments in oral insulin to manage patients with diabetes.
Drs Diana Isaacs and Natalie Bellini compare dosing of inhaled insulin to injectable insulin for the management of diabetes.
In the December 2022 episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss recent developments in the field, with a spotlight on the Dexcom G7 CGM, key takeaways from the ADA’s Standards of Care in Diabetes—2023, and perspective from the ADCES Diabetes Technology Conference 2022.
In this episode of Diabetes Dialogue, Jill Weissberg-Benchell, PhD, takes hosts through her journey to becoming a diabetes care and education specialist, the role of psychologists in the management of pediatric diabetes, and her thoughts on the evolving role of care and education specialists in the management of diabetes.
In this episode of Diabetes Dialogue, Richard Bergenstal, MD, sits down with hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss the role and evolution of technology in the management of diabetes.
Dr Diana Isaacs and Dr Natalie Bellini review adverse effects of inhaled insulin in patients with T1D and T2D.
An expert endocrine clinical pharmacist and nurse practitioner discuss clinical trial data on how inhaled insulin affects glucose management in T1D and T2D.
In this episode of Diabetes Dialogue, Jane Jeffrie Seley, DNP, MPH, a member of the writing committee for the ADA's Standards of Care in Diabetes—2023, joins the podcast to discuss pertinent updates in the sections of the document discussing inpatient management of diabetes within the document.
Drs Diana Isaacs and Natalie Bellini share the FDA-approved patient populations for inhaled insulin use to manage diabetes, as well as who would not be a good candidate.
Experts examine the use of Technosphere insulin, how it is delivered to the body, and the qualities of an ideal rapid-acting insulin analog in type 1 and type 2 diabetes.
Drs Diana Isaacs and Natalie Bellini discuss the limitations of injectable insulins in achieving time-in-range and glucose targets in type 1 and type 2 diabetes.
